INTRODUCTION: There is a clinical need for developing systemic transplantation protocols for use of @entity1 skeletal stem cells (also known bone marrow stromal stem cells) (hBMSC) in tissue regeneration. In systemic transplantation studies, only a limited number of hBMSC home to injured tissues suggesting that only a subpopulation of hBMSC possesses "homing" capacity. Thus, we tested the hypothesis that a subpopulation of hBMSC defined by ability to form heterotopic bone in vivo, is capable of homing to injured bone. METHODS: We tested ex vivo and in vivo homing capacity of a number of clonal cell populations derived from telomerized hBMSC ( @entity2215 ) with variable ability to form heterotopic bone when implanted subcutaneously in immune deficient @entity19 . In vitro transwell migration assay was used and the in vivo homing ability of transplanted hBMSC to @entity174 in @entity19 was visualized by bioluminescence imaging (BLI). In order to identify the molecular phenotype associated with enhanced migration, we carried out comparative DNA microarray analysis of gene expression of hBMSC-derived high bone forming (HBF) clones versus low bone forming (LBF) clones. RESULTS: HBF clones were exhibited higher ex vivo transwell migration and following intravenous injection, better in vivo homing ability to bone @entity174 when compared to LBF clones. Comparative microarray analysis of HBF versus LBF clones identified enrichment of gene categories of chemo-attraction, adhesion and migration associated genes. Among these, @entity3820 ( @entity3820 ) a and b were highly expressed in HBF clones. Follow up studies showed that the chemoattractant effects of PDGF in vitro was more enhanced in HBF compared to LBF clones and this effect was reduced in presence of a @entity3820 -specific inhibitor: SU-16  f. Also, PDGF exerted greater chemoattractant effect on @entity3820 (+) cells sorted from LBF clones compared to @entity3820 (-) cells. CONCLUSION: Our data demonstrate phenotypic and molecular association between in vivo bone forming ability and migratory capacity of hBMSC. @entity3820 can be used as a potential marker for the prospective selection of hBMSC populations with high migration and bone formation capacities suitable for clinical trials for enhancing bone regeneration.

Association between in vivo bone formation and ex vivo migratory capacity of XXXX bone marrow stromal cells.

@entity1 :: ('9606', 'Species') :: ['human'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture', 'bone fractures'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity3820 :: ('5159', 'Gene') :: ['PDGFR', 'platelet-derived growth factor receptor', 'PDGFRb'] @entity2215 :: ('7015', 'Gene') :: ['hBMSC-TERT']
@entity1 :: (9606,Species) :: ['human']
